MegaPro Biomedical Co., Ltd
MegaPro Biomedical Co., Ltd, a biotech company, focuses on the development of nano drugs. It also develops MPB-1523, an IOP injection that is in Phase II clinical trial for use in the treatment of hepatocellular carcinoma; and MPB-1514, an iron injection that is in Phase II clinical trial for use in the treatment of iron deficiency anemia, as well as MPB-1734, an anti-cancer drug that is in precl… Read more
MegaPro Biomedical Co., Ltd (6827) - Total Assets
Latest total assets as of June 2025: NT$162.36 Million TWD
Based on the latest financial reports, MegaPro Biomedical Co., Ltd (6827) holds total assets worth NT$162.36 Million TWD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
MegaPro Biomedical Co., Ltd - Total Assets Trend (2020–2024)
This chart illustrates how MegaPro Biomedical Co., Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
MegaPro Biomedical Co., Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
MegaPro Biomedical Co., Ltd's total assets of NT$162.36 Million consist of 77.8% current assets and 22.2% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 39.1% |
| Accounts Receivable | NT$1.49 Million | 0.7% |
| Inventory | NT$0.00 | 0.0% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$9.31 Million | 4.2% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how MegaPro Biomedical Co., Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: MegaPro Biomedical Co., Ltd's current assets represent 77.8% of total assets in 2024, a decrease from 85.5% in 2020.
- Cash Position: Cash and equivalents constituted 39.1% of total assets in 2024, up from 35.9% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 11.0% in 2020.
- Asset Diversification: The largest asset category is intangible assets at 4.2% of total assets.
MegaPro Biomedical Co., Ltd Competitors by Total Assets
Key competitors of MegaPro Biomedical Co., Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
MegaPro Biomedical Co., Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - MegaPro Biomedical Co., Ltd generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - MegaPro Biomedical Co., Ltd is currently not profitable relative to its asset base.
MegaPro Biomedical Co., Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.34 | 14.02 | 17.77 |
| Quick Ratio | 4.34 | 14.02 | 17.77 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$92.55 Million | NT$ 230.49 Million | NT$ 263.33 Million |
MegaPro Biomedical Co., Ltd - Advanced Valuation Insights
This section examines the relationship between MegaPro Biomedical Co., Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.72 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -23.9% |
| Total Assets | NT$224.31 Million |
| Market Capitalization | $3.23K USD |
Valuation Analysis
Below Book Valuation: The market values MegaPro Biomedical Co., Ltd's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: MegaPro Biomedical Co., Ltd's assets decreased by 23.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for MegaPro Biomedical Co., Ltd (2020–2024)
The table below shows the annual total assets of MegaPro Biomedical Co., Ltd from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$224.31 Million | -23.85% |
| 2023-12-31 | NT$294.58 Million | -14.04% |
| 2022-12-31 | NT$342.68 Million | -20.79% |
| 2021-12-31 | NT$432.61 Million | +63.16% |
| 2020-12-31 | NT$265.14 Million | -- |